Sugi Predict

Sugi Predict / Targets / MAP3K6

MAP3K6

Mitogen-activated protein kinase kinase kinase 6 · O95382 · MAP3K6 on Sugi Atlas →

8,188 patent compounds predicted against MAP3K6, 6,819 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Lestaurtinib Lestaurtinib (SCHEMBL730955) 1.00 2/20
Lestaurtinib Lestaurtinib (SCHEMBL1649693) 1.00 2/20
SCHEMBL1019355 SCHEMBL1019355 0.58 2/20
SCHEMBL2512221 SCHEMBL2512221 0.57 2/20
SCHEMBL1857854 SCHEMBL1857854 0.52 2/20
SCHEMBL1855955 SCHEMBL1855955 0.51 2/20
SCHEMBL1860032 SCHEMBL1860032 0.51 2/20
SCHEMBL1860908 SCHEMBL1860908 0.51 2/20
SCHEMBL270275 SCHEMBL270275 0.50 2/20
SCHEMBL2743565 SCHEMBL2743565 0.48 2/20
SCHEMBL1858079 SCHEMBL1858079 0.47 2/20
SCHEMBL1862265 SCHEMBL1862265 0.47 2/20
SCHEMBL1070552 SCHEMBL1070552 0.46 2/20
SCHEMBL1021743 SCHEMBL1021743 0.45 2/20
SCHEMBL1523075 SCHEMBL1523075 0.45 2/20
SCHEMBL1524348 SCHEMBL1524348 0.44 2/20
SCHEMBL1856316 SCHEMBL1856316 0.44 2/20
SCHEMBL1865625 SCHEMBL1865625 0.44 2/20
SCHEMBL1856282 SCHEMBL1856282 0.44 2/20
SCHEMBL1861344 SCHEMBL1861344 0.44 2/20

Clinical trials — most relevant to MAP3K6 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma PHASE4UNKNOWN
Treatment With HMG-COA Reductase Inhibitor of Growth and Bone Abnormalities in Children With Noonan Syndrome PHASE3COMPLETED
HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma PHASE1/PHASE2COMPLETED
A Study to Evaluate RAF265, an Oral Drug Administered to Subjects With Locally Advanced or Metastatic Melanoma PHASE1/PHASE2COMPLETED
Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations PHASE2ACTIVE_NOT_RECRUITING
A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations PHASE2RECRUITING
Dabrafenib + Trametinib + PDR001 In Colorectal Cancer PHASE2UNKNOWN
Bevacizumab and Erlotinib in Treating Patients With Advanced Liver Cancer PHASE2COMPLETED
Cetuximab, Chemotherapy, and Radiation Therapy for Operable Stage III or IV Head and Neck Cancer PHASE2COMPLETED
Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva... PHASE2COMPLETED
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer PHASE2COMPLETED
To Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600+ Metastatic Melanoma in Focal Progression With First-line+Vemurafenib+Cobimetinib. PHASE2UNKNOWN
MEK162 for Patients With RAS/RAF/MEK Activated Tumors PHASE2COMPLETED
Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma PHASE1/PHASE2SUSPENDED
Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant PHASE2RECRUITING
Erlotinib Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia PHASE2COMPLETED
Perifosine in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma PHASE2COMPLETED
Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer PHASE1COMPLETED
Radiation Therapy and Bortezomib and Cetuximab With or Without Cisplatin to Treat Head and Neck Cancer PHASE1COMPLETED
A Study to Look at the Electrical Activity of the Heart in Subjects With Solid Tumor Cancers, Before and After Receiving the Study Treatment, GSK1120212 PHASE1COMPLETED
Nilotinib in Huntington's Disease PHASE1UNKNOWN
Evaluation of Human Melanocytes After the Use of PRP Versus Fractional CO2 Laser in Vitiligo nanUNKNOWN
Clinical, Genetic, and Epidemiologic Study of Children and Adults With RASopathies nanRECRUITING
Molecular Analysis of Thoracic Malignancies nanENROLLING_BY_INVITATION
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma nanCOMPLETED
Clinical Genetics Branch Eligibility Screening Survey nanNOT_YET_RECRUITING
Veristrat as Predictor of Benefit of First Line Non Small Cell Lung Cancer (NSCLC) Patients From Standard Chemotherapy nanUNKNOWN
Targeted Treatment Plus Tislelizumab and HAIC for Advanced CRCLM Failed From Standard Systemic Treatment nanACTIVE_NOT_RECRUITING
BRAF-/MEK-Inhibition With Dabrafenib and Trametinib in Melanoma Patients nanCOMPLETED
Histiocytic Disorder Follow-up Study nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a MAP3K6 binder may also engage these)

ProteinNameSimilarity
Q9WTR2 — 0.998 Q9WTR2 →
Q9Y613 — 0.987 Q9Y613 →
Q9R011 — 0.986 Q9R011 →
Q924T7 — 0.985 Q924T7 →
Q99MQ3 — 0.985 Q99MQ3 →
ERN2 Serine/threonine-protein kinase/endoribonuclease IRE2 0.984 landscape →
P70218 — 0.984 P70218 →
RNF31 E3 ubiquitin-protein ligase RNF31 0.983 landscape →
Q8BXP5 — 0.983 Q8BXP5 →
PLK3 Serine/threonine-protein kinase PLK3 0.983 landscape →
Q9Z2E3 — 0.983 Q9Z2E3 →
PINK1 Serine/threonine-protein kinase PINK1, mitochondrial 0.983 landscape →
B5DFG1 — 0.983 B5DFG1 →
Q99ML2 — 0.983 Q99ML2 →
Q6F5E8 — 0.982 Q6F5E8 →
B5DFA1 — 0.982 B5DFA1 →
Q80XI6 — 0.982 Q80XI6 →
A7E3S5 — 0.982 A7E3S5 →
Q8K045 — 0.981 Q8K045 →
P54265 — 0.981 P54265 →
Q7T0L4 — 0.981 Q7T0L4 →
TNK1 Non-receptor tyrosine-protein kinase TNK1 0.981 landscape →
CDC42BPG Serine/threonine-protein kinase MRCK gamma 0.981 landscape →
Q86TL0 — 0.981 Q86TL0 →
E6ZIJ1 — 0.981 E6ZIJ1 →
Q66HA1 — 0.980 Q66HA1 →
Q91ZJ0 — 0.980 Q91ZJ0 →
Q9UJY4 — 0.980 Q9UJY4 →
MUS81 Structure-specific endonuclease subunit MUS81 0.980 landscape →
Q6KAU8 — 0.980 Q6KAU8 →